Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02205333
Title A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Acronym MEDI6469
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MedImmune LLC
Age Groups: adult
Covered Countries USA

No variant requirements are available.